BACKGROUND: Many benign pulmonary lesions, especially sarcoidosis, are metabolically active and are indistinguishable from lung cancer using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging. This study sought to analyze the 18F-FDG PET/CT imaging features of benign pulmonary lesions and to improve the differential diagnosis of benign pulmonary lesions by 18F-FDG PET/CT imaging. METHODS: One hundred and thirteen patients with benign pulmonary lesions were studied retrospectively. Each patient underwent an 18F-FDG PET/CT scan. All cases were identified by pathology, diagnostic therapy or follow-up. The maximum standardized uptake value (SUVmax) was calculated for each pulmonary lesion. RESULTS: According to the final results, the benign pulmonary lesions were classified as inflammatory lesions (n=77) and granulomas (n=36) by histopathological diagnoses. The SUVmax of inflammatory lesions and granulomas were both high (4.55±2.77 and 6.81±3.96, respectively; P<0.05). When the benign pulmonary lesions were classified by clinical diagnoses, the SUVmax of sarcoidosis was significantly different from other diseases (15.12±5.67; P<0.01). CONCLUSIONS: Inflammatory lesions and granulomas show moderate or high FDG uptake on 18F-FDG PET/CT, but granulomas have higher values. 18F-FDG PET/CT appeared to have a higher SUVmax for the differential diagnosis of sarcoidosis and benign pulmonary lesions.
BACKGROUND: Many benign pulmonary lesions, especially sarcoidosis, are metabolically active and are indistinguishable from lung cancer using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging. This study sought to analyze the 18F-FDG PET/CT imaging features of benign pulmonary lesions and to improve the differential diagnosis of benign pulmonary lesions by 18F-FDG PET/CT imaging. METHODS: One hundred and thirteen patients with benign pulmonary lesions were studied retrospectively. Each patient underwent an 18F-FDG PET/CT scan. All cases were identified by pathology, diagnostic therapy or follow-up. The maximum standardized uptake value (SUVmax) was calculated for each pulmonary lesion. RESULTS: According to the final results, the benign pulmonary lesions were classified as inflammatory lesions (n=77) and granulomas (n=36) by histopathological diagnoses. The SUVmax of inflammatory lesions and granulomas were both high (4.55±2.77 and 6.81±3.96, respectively; P<0.05). When the benign pulmonary lesions were classified by clinical diagnoses, the SUVmax of sarcoidosis was significantly different from other diseases (15.12±5.67; P<0.01). CONCLUSIONS: Inflammatory lesions and granulomas show moderate or high FDG uptake on 18F-FDG PET/CT, but granulomas have higher values. 18F-FDG PET/CT appeared to have a higher SUVmax for the differential diagnosis of sarcoidosis and benign pulmonary lesions.
Authors: Suzanne Rogers; Maria L Macheda; Susan E Docherty; Maynard D Carty; Michael A Henderson; Walter C Soeller; E Michael Gibbs; David E James; James D Best Journal: Am J Physiol Endocrinol Metab Date: 2002-03 Impact factor: 4.310
Authors: Stephanie L Davis; Eric L Nuermberger; Peter K Um; Camille Vidal; Bruno Jedynak; Martin G Pomper; William R Bishai; Sanjay K Jain Journal: Antimicrob Agents Chemother Date: 2009-09-08 Impact factor: 5.191
Authors: James W Fletcher; Steven M Kymes; Michael Gould; Naomi Alazraki; R Edward Coleman; Val J Lowe; Charles Marn; George Segall; Lyn A Thet; Kelvin Lee Journal: J Nucl Med Date: 2008-01-16 Impact factor: 10.057
Authors: Vera Wenter; Nathalie L Albert; Freba Ahmaddy; Marcus Unterrainer; Julia Hornung; Harun Ilhan; Peter Bartenstein; Christine Spitzweg; Nikolaus Kneidinger; Andrei Todica Journal: BMC Cancer Date: 2021-02-07 Impact factor: 4.430
Authors: Francesco Cattelan; Elvis Hysa; Emanuele Gotelli; Carmen Pizzorni; Pietro Francesco Bica; Marco Grosso; Emanuela Barisione; Sabrina Paolino; Luca Carmisciano; Alberto Sulli; Vanessa Smith; Maurizio Cutolo Journal: Rheumatol Int Date: 2022-08-30 Impact factor: 3.580